“A Pfizer study on the Anti-covid pill confirms the drug’s effectiveness in preventing severe disease.” So announced the American company.
Pfizer also added that “the pill, from laboratory studies, is effective against the omicron variant.” The CEO Albert Bourla he also declared “we are sure that, if authorized or approved, this pill could be a decisive tool in fighting the pandemic”.
Anti Covid pills work but they cannot replace vaccines: here’s why
by Aureliano Stingi
Paxlovid, the drug’s brand name, “must be administered within the first three days of symptoms and reduces hospitalizations and death by 89 percent,” the company said in today’s announcement.
Anti covid pill: green light from the ministry for the purchase of 100 thousand Merck and Pfizer cycles
Ema evaluates the efficacy data of Merck’s anti Covid pill
The European Medicines Agency is reviewing new data on the effectiveness of the drug Lagevrio (molnupiravir, the Merck pill) for the treatment of Covid-19 in support of national authorities who can decide on early use of the medicine before authorization. EU to be placed on the market.
This is what we learn from a note from the EMA. The updated results, based on 1,408 subjects, show that Lagevrio reduced the risk of hospitalization or death in people with Covid-19, who were in danger of contracting severe forms of the disease, from 9.7% in the placebo group to 6.8. % in the Lagevrio group. The previous recommendations remain unchanged.
Covid Merck pill, new data on effectiveness and FDA doubts about safety
The EMA will further communicate the outcome of the marketing authorization application currently under review. Lagevrio is an oral antiviral medicine that reduces the ability of SARS-CoV-2 to multiply in the body. It does this by increasing the number of alterations in the genetic material of the virus (known as Rna) in a way that impairs SARS-CoV-2’s ability to multiply. Lagevrio is developed by Merck Sharp & Dohme in collaboration with Ridgeback Biotherapeutics.